Buprenorphine reduces methamphetamine intake and drug seeking behavior activating nociceptin/orphanin FQ peptide receptor in rats.
Fiche publication
Date publication
octobre 2022
Journal
Frontiers in psychiatry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KOHLI Evelyne
Tous les auteurs :
Wang F, Shen W, Cai Y, Zhang X, Du H, Lai M, Liu H, Kohli E, Zhou W
Lien Pubmed
Résumé
Buprenorphine, which has been approved for the treatment of opioid dependence, reduces cocaine consumption by co-activating μ-opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. However, the role of buprenorphine in methamphetamine (METH) reinforcement and drug-seeking behavior remains unclear. This study investigated the effects of buprenorphine on METH self-administration and reinstatement of METH-seeking behavior in rats. We found that buprenorphine pretreatment had an inhibitory effect on METH self-administration behavior, and that buprenorphine at a dose of 0.3 mg/kg could inhibit motivation to respond for METH. Pretreatment with the NOP receptor antagonist thienorphine (0.5 mg/kg) or SB-612111 (1 mg/kg) could reverse the inhibitory effect of buprenorphine (0.1 mg/kg) on the METH self-administration. Moreover, treatment with buprenorphine (0.1 mg/kg and 0.3 mg/kg) significantly reduced the drug-seeking behavior induced by context or by METH priming but failed to reduce the drug-seeking behavior induced by conditional cues. Additionally, the NOP receptor antagonist SB-612111 reversed the inhibitory action of buprenorphine on the drug-seeking behavior induced by METH priming. The results demonstrated that buprenorphine reduced either METH intake or the drug-seeking behavior by activating NOP receptors, providing empirical evidence for the clinical use of buprenorphine in the treatment of METH relapse and addiction.
Mots clés
buprenorphine, methamphetamine, nociceptin/orphanin FQ peptide, opioid receptor, substance use disorder
Référence
Front Psychiatry. 2022 10 6;13:983595